Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) Research & Development (2016 - 2025)

Rein Therapeutics filings provide 10 years of Research & Development readings, the most recent being $2.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 39.77% year-over-year to $2.0 million, compared with a TTM value of $11.0 million through Dec 2025, down 22.6%, and an annual FY2025 reading of $11.0 million, down 22.59% over the prior year.
  • Research & Development hit $2.0 million in Q4 2025 for Rein Therapeutics, up from $1.7 million in the prior quarter.
  • The five-year high for Research & Development was $5.9 million in Q1 2022, with the low at $22000.0 in Q3 2023.
  • Median Research & Development over the past 5 years was $3.6 million (2024), compared with a mean of $3.2 million.
  • The sharpest move saw Research & Development plummeted 99.48% in 2023, then surged 16818.18% in 2024.
  • Year by year, Research & Development stood at $4.6 million in 2021, then tumbled by 47.34% to $2.4 million in 2022, then dropped by 17.9% to $2.0 million in 2023, then soared by 68.46% to $3.3 million in 2024, then plummeted by 39.77% to $2.0 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $2.0 million, $1.7 million, and $4.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.